Small macrocyclic C5a complement antagonists achieved meaningful transdermal delivery in rats, demonstrating that cyclic peptide drugs can penetrate skin — opening topical administration for anti-inflammatory peptide therapy.
Key findingMacrocyclic C5a antagonists achieved pharmacologically active transdermal penetration in rats, with measurable anti-inflammatory effects from topical
What the researchers found
Macrocyclic C5a antagonists achieved pharmacologically active transdermal penetration in rats, with measurable anti-inflammatory effects from topical application — establishing the feasibility of transdermal delivery for cyclic peptide anti-inflammatory drugs.
Why it matters
Relevant for cyclic-peptides, inflammation, peptide-delivery.
How the study worked
animal-study study on cyclic-peptides, inflammation.
What this study cannot tell us
See abstract.
How to read the evidence
preliminary evidence.
When this study was published
Published in 2006.
The bigger picture
Advances peptide research.
Questions still open
- Further research needed.
- Clinical translation to evaluate.
Common questions
What was studied?
What was found?
Read the original research
Transdermal pharmacology of small molecule cyclic C5a antagonists.
Advances in experimental medicine and biology, 586, 329-45
Citation
Proctor, Lavinia M; Woodruff, Trent M; Sharma, Prakirti; Shiels, Ian A; Taylor, Stephen M. (2006). Transdermal pharmacology of small molecule cyclic C5a antagonists.. Advances in experimental medicine and biology, 586, 329-45.